我们表明,DM002 BSAB可以与HER3和MUC1表达不同的肿瘤细胞结合,并以高于其父母mAb的速率内化,这表明这两个臂之间的协同作用。In vivo, DM002 bsADC, both as vcMMAE conjugates and as novel DNA topoisomerase I inhibitor linker/payload conjugates (BLD1102) potently inhibited growth of HER3 and MUC1 double positive PDX tumors and showed more potent in vivo efficacy than mono-Ab ADCs, consistent with their in vitro internalization findings.The potential indications of DM002研究的重点是肺癌,乳腺癌,CRC,胰腺癌,卵巢癌和胃癌。
主要关键词